Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Travere Therapeutics Inc (TVTX)

Travere Therapeutics Inc (TVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,340,899
  • Shares Outstanding, K 78,050
  • Annual Sales, $ 145,240 K
  • Annual Income, $ -111,400 K
  • EBIT $ -381 M
  • EBITDA $ -348 M
  • 60-Month Beta 0.69
  • Price/Sales 9.35
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 71.32% ( -2.84%)
  • Historical Volatility 49.26%
  • IV Percentile 25%
  • IV Rank 33.04%
  • IV High 171.71% on 08/16/24
  • IV Low 21.77% on 07/15/24
  • Put/Call Vol Ratio 2.14
  • Today's Volume 44
  • Volume Avg (30-Day) 200
  • Put/Call OI Ratio 0.71
  • Today's Open Interest 27,953
  • Open Int (30-Day) 27,049

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.61
  • Number of Estimates 8
  • High Estimate -0.49
  • Low Estimate -0.77
  • Prior Year -1.16
  • Growth Rate Est. (year over year) +47.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.66 +3.12%
on 12/18/24
19.99 -14.06%
on 12/03/24
-0.68 (-3.81%)
since 11/20/24
3-Month
13.24 +29.76%
on 10/03/24
20.33 -15.49%
on 11/11/24
+1.97 (+12.95%)
since 09/20/24
52-Week
5.12 +235.55%
on 04/25/24
20.33 -15.49%
on 11/11/24
+8.84 (+106.00%)
since 12/20/23

Most Recent Stories

More News
Insider Sale: SVP of $TVTX (TVTX) Sells 12,090 Shares

Sandra Calvin, the SVP of $TVTX ($TVTX), sold 12,090 shares of the company on 11-25-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 18.0% of their shares....

TVTX : 17.18 (-1.26%)
Travere Therapeutics to Present at Upcoming Investor Conferences

TVTX : 17.18 (-1.26%)
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

TVTX : 17.18 (-1.26%)
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

TVTX : 17.18 (-1.26%)
3 Under-the-Radar Healthcare Companies

While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains.

NTRA : 161.88 (+2.40%)
TVTX : 17.18 (-1.26%)
XLV : 138.00 (+1.26%)
MCK : 579.74 (+0.09%)
UNH : 500.13 (+2.22%)
THC : 129.46 (+2.99%)
Travere Therapeutics Announces Pricing of Public Offering of Common Stock

TVTX : 17.18 (-1.26%)
Travere Therapeutics Announces Proposed Public Offering of Common Stock

TVTX : 17.18 (-1.26%)
Travere Therapeutics to Present at Upcoming Investor Conferences

TVTX : 17.18 (-1.26%)
Travere: Q3 Earnings Snapshot

Travere: Q3 Earnings Snapshot

TVTX : 17.18 (-1.26%)
Travere Therapeutics Reports Third Quarter 2024 Financial Results

TVTX : 17.18 (-1.26%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Travere Therapeutics Inc. is a biopharmaceutical company. It engages to identify, develop and deliver life-changing therapies. Travere Therapeutics Inc., formerly known as Retrophin Inc., is based in SAN DIEGO.

See More

Key Turning Points

3rd Resistance Point 18.41
2nd Resistance Point 18.15
1st Resistance Point 17.66
Last Price 17.18
1st Support Level 16.91
2nd Support Level 16.65
3rd Support Level 16.16

See More

52-Week High 20.33
Last Price 17.18
Fibonacci 61.8% 14.52
Fibonacci 50% 12.73
Fibonacci 38.2% 10.93
52-Week Low 5.12

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar